[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100657682":3},{"organization":4,"outcomesModule":7,"designInfo":20,"detailedDescription":28,"studyPopulation":19,"armGroups":29,"interventions":41,"overallOfficials":51,"centralContacts":55,"locations":64,"responsibleParty":80,"collaborators":19,"id":82,"slug":83,"hasResults":84,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":19,"eligibilityCriteria":88,"healthyVolunteers":84,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":19,"studyType":95,"phases":96,"briefSummary":99,"conditions":100,"keywords":103,"overallStatus":66,"whyStopped":19,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Price Vision Group","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":19},[9],{"measure":10,"description":11,"timeFrame":12},"Change in maximum keratometry","assessed with corneal tomography","6 months",[14,17],{"measure":15,"description":16,"timeFrame":12},"change in corrected distance visual acuity","assessed with Snellen chart",{"measure":18,"description":16,"timeFrame":12},"change in uncorrected distance visual acuity",null,{"allocation":21,"interventionModel":22,"interventionModelDescription":19,"primaryPurpose":23,"observationalModel":19,"timePerspective":19,"maskingInfo":24},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":25,"maskingDescription":19,"whoMasked":26},"SINGLE",[27],"OUTCOMES_ASSESSOR","Subjects diagnosed with keratoconus or corneal ectasia are randomized to one of two corneal crosslinking light durations.",[30,36],{"label":31,"type":32,"description":33,"interventionNames":34},"Pulsed","ACTIVE_COMPARATOR","Treatment with 0.1% riboflavin eye drops and pulsed 18 milliwatt\u002Fcm2 ultraviolet A light for 10 minutes",[35],"Combination Product: Riboflavin 0.1% ophthalmic solution and pulsed light",{"label":37,"type":32,"description":38,"interventionNames":39},"Non-pulsed","Treatment with 0.1% riboflavin eye drops non-pulsed 9 milliwatt\u002Fcm2 ultraviolet A light for 10 minutes",[40],"Combination Product: Riboflavin 0.1% ophthalmic solution and non-pulsed light",[42,47],{"type":43,"name":44,"description":45,"armGroupLabels":46,"otherNames":19},"COMBINATION_PRODUCT","Riboflavin 0.1% ophthalmic solution and pulsed light","Use of riboflavin 0.1% eye drops and pulsed 18 milliwatt\u002Fcm2 ultraviolet A light for 10 minutes",[31],{"type":43,"name":48,"description":49,"armGroupLabels":50,"otherNames":19},"Riboflavin 0.1% ophthalmic solution and non-pulsed light","Use of riboflavin 0.1% eye drops and non-pulsed 9 milliwatt\u002Fcm2 ultraviolet A light for 10 minutes",[37],[52],{"name":53,"affiliation":5,"role":54},"Francis Price, MD","PRINCIPAL_INVESTIGATOR",[56,61],{"name":57,"role":58,"phone":59,"phoneExt":19,"email":60},"Marianne Price, PhD","CONTACT","317-814-2990","mprice@cornea.org",{"name":53,"role":58,"phone":62,"phoneExt":19,"email":63},"317-814-2823","fprice@pricevisiongroup.net",[65],{"facility":5,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"RECRUITING","Indianapolis","Indiana","46260","United States","US",{"type":73,"coordinates":74},"Point",[75,76],-86.15804,39.76838,{"lat":76,"lon":75},[79],{"name":57,"role":58,"phone":59,"phoneExt":19,"email":60},{"type":81,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100657682","phase-2-corneal-crosslinking-for-treatment-of-progressive-keratoconus-or-corneal-ectasia-100657682",false,"NCT07841470","Corneal Crosslinking for Treatment of Progressive Keratoconus or Corneal Ectasia","Corneal Crosslinking for Treatment of Progressive Keratoconus or Ectasia: Randomized Comparison of Pulsed vs. Non-pulsed Treatment","Inclusion Criteria:\n\n* Diagnosis of keratoconus or corneal ectasia\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Previous ocular condition in the study eye that may predispose for future complications including history of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.)\n* Clinically significant corneal scarring in the proposed treatment zone\n* History of chemical injury or delayed epithelial healing in the study eye\n* Known sensitivity to study medication\n* A current condition, including clinically significant dry eyes or use of medications know to induce dry eye symptoms, that, in the treating physician's opinion, would interfere with or prolong epithelial healing\n* Pregnancy (including plan to become pregnant) or lactation during the course of the study","ALL","10 Years","90 Years",{"count":93,"type":94},500,"ESTIMATED","INTERVENTIONAL",[97,98],"PHASE2","PHASE3","This randomized study compares 2 variations of corneal crosslinking for treatment of keratoconus or corneal ectasia.",[101,102],"Keratoconus","Corneal Ectasia",[104,105],"crosslinking","keratoconus","2026-09-24",{"date":108,"type":109},"2026-09-25","ACTUAL",{"date":111,"type":109},"2025-10-01",{"date":113,"type":94},"2031-06-30",{"name":5,"class":6},1]